MedTrace Logo

Aflibercept for Diabetic Macular Edema In Real-life Practice in GREece

NCT05683912 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2023-01-13

No results posted yet for this study

Summary

ADMIRE was a prospective, observational cohort study of patients with diabetic macular edema (DME). Efficacy was assessed by change in best-corrected visual acuity (BCVA) and central retinal thickness (CRT) from baseline to months 12, 24 and 36 after treatment with intravitreal aflibercept in treatment-naïve patients and previously treated patients. Safety was evaluated by recording any patients-reported events.

Conditions

Interventions

DRUG

Aflibercept

Intravitreal aflibercept as used in the routice clinical practice

Sponsors & Collaborators

  • University of Athens

    lead OTHER

Eligibility

Min Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-01
Primary Completion
2021-09-01
Completion
2022-12-15

Countries

  • Greece

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05683912 on ClinicalTrials.gov